Cantor Fitzgerald Reiterates “Overweight” Rating for 89bio (NASDAQ:ETNB)
(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...
89bio (NASDAQ:ETNB) Trading Down 3.7% – Here’s What Happened
Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...
Investing4d
89bio's SWOT analysis: pegozafermin potential drives stock outlook
89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate ...
Cantor Fitzgerald Reaffirms Their Buy Rating on 89bio (ETNB)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...
Zacks.com on MSN7h
New Strong Sell Stocks for January 7th
89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days.
Investing4d
89bio's SWOT analysis: pegozafermin potential drives stock outlook
89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.
GlobalData on MSN3d
Expanding diagnostic and biomarker options to improve MASH clinical trials
Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...